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Background: Tumor-associated macrophages (TAM) promote malignant progression, yet the repertoire of
oncogenic factors secreted by TAM has not been clearly defined. We sought to analyze which EGFR- and STAT3-
activating factors are secreted by monocytes/macrophages exposed to tumor cell-secreted factors.
Methods: Following exposure of primary human monocytes and macrophages to supernatants of a variety of
tumor cell lines, we have analyzed transcript and secreted protein levels of EGFR family ligands and of STAT3
activators. To validate our findings, we have analyzed TAM infiltration levels, systemic and local protein levels as
well as clinical data of primary breast cancer patients.
Results: Primary human monocytes and macrophages respond to tumor cell-derived factors by secreting EGFR-
and STAT3-activating ligands, thus inducing two important oncogenic pathways in carcinoma cells. Tumor cell-
secreted factors trigger two stereotype secretory profiles in peripheral blood monocytes and differentiated
macrophages: monocytes secrete epiregulin (EREG) and oncostatin-M (OSM), while macrophages secrete heparin-
binding EGF-like growth factor (HB-EGF) and OSM. HB-EGF and OSM cooperatively induce tumor cell chemotaxis.
HB-EGF and OSM are co-expressed by TAM in breast carcinoma patients, and plasma levels of both ligands
correlate strongly. Elevated HB-EGF levels accompany TAM infiltration, tumor growth and dissemination in patients
with invasive disease.
Conclusions: Our work identifies systemic markers for TAM involvement in cancer progression, with the potential
to be developed into molecular targets in cancer therapy.
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Molecular targeting of cancer cells has proven to be an
extremely effective approach in tumor therapy. However,
the inherent genomic instability of tumor cells promotes
the establishment of therapy-refractory cancer cell clones
during the course of treatment [1].
In addition, recent studies of the tumor microenvi-
ronment have emphasised that cancer cells effectively
reprogram infiltrating immune cells, to the point where
they support malignant progression [2]. Tumor-associated* Correspondence: ullrich@biochem.mpg.de
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reproduction in any medium, provided the ormacrophages (TAM) are key participants in the cross-
talk between tumor and immune cells. Thus, these
genomically stable cells represent promising targets for
anticancer therapy. TAM density correlates with poor
prognosis in a considerable number of human cancers
[3]. Their best studied contribution to malignancy is the
involvement in tumor progression. In a mouse breast car-
cinoma model, Pollard and colleagues have shown that
macrophage (MΦ) ablation inhibits metastasis [4]. MΦ
exert important functions as trophic agents by secreting a
plethora of growth factors and metalloproteases [5,6].
With TAM being the most thoroughly studied compo-
nents of the innate immune system, less is known about
the impact of tumor-associated monocytes on tumortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cytes promote angiogenesis in a mouse tumor model [7].
We studied the influence of tumor cells on ligand
transcription and secretion patterns of monocytes and
differentiated macrophages. Given the pivotal roles the
oncogenic STAT3 and EGFR pathways play in tumor de-
velopment [8,9], we focused primarily on the repertoire
of interleukin-6-like STAT3 activators and EGFR ago-
nists secreted by tumor-primed monocytes and MΦ.
Apart its founder protein, the interleukin-6 cytokine
family includes interleukin-11 (IL-11), leukemia inhibi-
tory factor (LIF), ciliary neurotrophic factor (CNTF),
cardiotrophin-1 (CT-1) and oncostatin-M (OSM). The
group of epidermal growth factor-like ligands contains
seven EGFR agonists: amphiregulin (AREG), betacellulin
(BTC), epidermal growth factor (EGF), epigen (EPGN),
epiregulin (EREG), heparin-binding EGF-like growth
factor (HB-EGF) and transforming growth factor alpha
(TGFα). Several lines of evidence point to a role of
TAM-secreted EGFR ligands in malignant progression.
McGee and colleagues provided clues for EGF production
by TAM in breast carcinoma biopsies [10]. TAM number
and EGFR expression levels correlate in human breast tu-
mors [11], and TAM induce the EGFR-dependent migra-
tion of tumor cells in a murine breast carcinoma model
[12]. However, the exact repertoire of TAM-secreted
EGFR agonists is unknown, as are the related regulatory
pathways.
Our work demonstrates that in response to tumor
cell-derived factors, mononuclear cells in turn secrete
oncogenic ligands. Subsequent to priming with tumor
cell-secreted factors, human primary MΦ and peripheral
blood monocytes (PBMC) both secrete OSM, but each
cell type in combination with one specific EGFR agonist.
These findings reveal characteristic secretory patterns of
tumor-primed MΦ and PBMC in vitro, regardless of
tumor etiology.
Methods
Ethics statement
This study was approved by the responsible ethics com-
mittee of the Ludwig-Maximilians-University, Munich,
project nr. 189-11.
Cell lines
HL-60, MDA-MB-231, T-47D, MCF7, MDA-MB-468,
MDA-MB-435S, SCC-9 and MCF 10A cell lines were
obtained from the American Type Culture Collection
(Manassas, VA). Primary HMEC were obtained from
Clonetics (Basel, Switzerland) and cultured in MEGM®
medium (Lonza, Walkersville, MD). HL-60, MDA-MB-
231, MCF7, MDA-MB-468 and MDA-MB-435S cells were
cultured in RPMI1640 containing 10% heat-inactivated
fetal bovine serum (Invitrogen, Grand Island, NY). T-47Dcells were cultured in RPMI1640 containing 10% heat-
inactivated fetal bovine serum and 10 μg/ml bovine insulin
(Sigma, St. Louis, MO). SCC-9 cells were cultured in
DMEM/Ham’s F-12 (1:1) containing 10% heat-inactivated
fetal bovine serum and 0.4 μg/ml hydrocortisone (Sigma).
MCF 10A cells were cultured in DMEM/Ham’s F-12 (1:1)
containing 5% heat-inactivated horse serum (Invitrogen),
0.5 μg/ml hydrocortisone, 20 ng/ml EGF (PeproTech,
Hamburg, Germany), 10 μg/ml bovine insulin, 0.1 μg/ml
cholera toxin (Sigma). All culture media contained 100
Units/ml Penicillin and 0.1 mg/ml Streptomycin (PAA,
Pasching, Austria). Cells were cultured at 37°C in humidi-
fied air under 5% CO2 and were confirmed to be devoid of
mycoplasma.
Monocyte isolation and macrophage differentiation
Peripheral blood was collected from healthy human do-
nors after obtaining informed written consent. 15 ml of
EDTA-treated blood were layered over a Ficoll-Paque™
PLUS column (GE Healthcare, Piscataway, NJ) and
centrifuged at 400 g for 30 minutes, at 18°C. Leukocytes
were washed twice with ice-cold PBS and transferred
into RPMI containing 10% heat-inactivated fetal bovine
serum and 5% active human serum. Following adher-
ence to gelatine-coated culture plates (Sigma) that had
been freshly precoated with human plasma, monocytes
were washed 5 times with warm washing buffer (RPMI
and PBS; 1:1), then detached using 5 mM EDTA in
washing buffer. Cells were collected, centrifuged at
400 g for 15 minutes at 4°C then washed twice with ice-
cold washing buffer. PBMC were plated at a density of
1.0 × 106 cells/ml in 6 well culture plates (Corning,
Corning, NY) in monocyte culture medium (RPMI
supplemented with 5% normal human male AB serum,
Sigma). After 4 days of cultivation, cells were washed 3
times with RPMI and received fresh culture medium.
Between day 4 and 10, medium was changed every third
day. After 7 days of culture, macrophages had completed
spontaneous differentiation.
Migration assays
Unless otherwise stated, cells were plated into transwell
migration inserts (BD Biosciences, Bedford, MA) using
RPMI + 0.1% BSA. The lower compartments contained
either serum-free MΦ supernatants, culture media or
RPMI + 0.1% BSA with or without OSM/HB-EGF. Where
indicated, a 1 hr preincubation with neutralising anti-
bodies, DMSO or AG1478 was performed prior to cell
plating. At the end of the migration period, cells were
fixed and stained with 20% methanol, 0.5% crystal violet
and cotton swabs were used to remove the cells from the
upper side of the membrane. An Axio Observer.A1 micro-
scope (Carl Zeiss, Jena, Germany) was used to record 5
micrographs per well. Photoshop CS4 (Adobe, San Jose,
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quantification of migration 5 × 104 SCC-9 cells were
allowed to migrate for 6 hrs (chemotaxis) or 17 hrs (intrin-
sic motility). 1.5 × 105 MCF 10A cells were allowed to
migrate for 17 hrs. 1.5 × 105 MCF7 cells were allowed to
migrate for 48 hrs.
Statistical analysis
Two-tailed Mann–Whitney U-Tests were used for
qPCR and ELISA experiments. For immunoblot, motil-
ity and chemotaxis experiments we used the two-tailed
Student’s T-Test. Differences were considered signifi-
cant when p < 0.05. Data are presented as means ± SEM
or SD.
Results
Tumor cells and primary mononuclear cells interact via
secreted factors
To analyse paracrine interactions via secreted factors,
we designed an experimental setup based on the priming
of primary human mononuclear cells with supernatants
from a panel of human tumor and nontransformed cells.
In contrast to direct coculture, such priming experi-
ments permit a thorough analysis of factors secreted by
both cell types, at protein and transcript level. Figure 1A
provides our model of tumor cell/mononuclear cell
interaction, based on mutually secreted factors. In vivo,
tumor-derived soluble factors trigger the extravasation
of PBMC in the vicinity of tumor cells [13]. This implies
that tumor-primed PBMC already participate in the
crosstalk between tumor cells and microenvironment.
Following differentiation from extravasated PBMC, TAM
are exposed to tumor-derived priming factors and release
soluble oncogenic factors. In vitro, PBMC differentiate
spontaneously to MΦ in the presence of human serum
(Additional file 1: Figure S1A/B). To study the effects of
tumor-secreted factors on primary human mononuclear
cells in vitro, we primed PBMC or MΦ with tumor cell-
supernatants for 24 hrs. Subsequent to priming, PBMC-
or MΦ-conditioned media were used to stimulate reporter
cells. MDA-MB-231 cells served as indicators of STAT3
activators present in the supernatants. SCC-9 cells, an
established model for EGFR activation studies [14], were
used as indicators of EGFR agonists secreted by PBMC/
MΦ. Our experimental approach is presented in Figure 1B.
Transcript analysis of PBMC and MΦ revealed that four
EGFR agonists were expressed. In detail, we identified
AREG, EREG, HBEGF and TGFA transcripts in both tested
cell types. In contrast, BTC, EGF and EPGN transcripts
were not detected. In addition, PBMC and MΦ expressed
oncostatin-M, a STAT3 activator of the IL-6 family previ-
ously identified as a monocyte-secreted factor via mass
spectrometric analysis (Additional file 1: Figure S1C and
data not shown). While OSM was only expressed bymyeloid cells, both OSM-specific receptors, OSMRβ
and LIFR, were exclusively expressed by cells of epithe-
lial origin (Additional file 1: Figure S2). This finding
points at possible paracrine interactions between EGFR
ligand- and OSM-expressing mononuclear cells and
EGFR- and OSMRβ/LIFR-expressing carcinoma cells.
Tumor cell-derived factors trigger divergent patterns of
transcriptional activity and ligand secretion in PBMC and
MΦ
To study the priming effects of tumor cell-secreted factors
on primary human mononuclear cells, we used diluted
MDA-MB-231 supernatants (1:2). Subsequent to priming,
transcript and secreted protein levels of EGFR ligands and
OSM were monitored. Priming by tumor cells upregulated
EREG, TGFA and OSM transcripts in PBMC within
24 hrs, as shown by qPCR analysis (Figure 2A). Primed
PBMC secreted factors that significantly induced pEGFR
levels in the reporter cell line. We tested neutralising
antibodies directed against AREG, EREG, HB-EGF and
TGFα in order to identify the EGFR agonists secreted
by primed PBMC. The used antibodies display no sig-
nificant crossreactivity towards other EGFR ligands
(Additional file 1: Figure S3). Epiregulin neutralisation
by an inhibitory antibody reduced pEGFR to basal
levels. Though highly expressed at transcript level, a
TGFα blocking antibody had no effect (Figure 2B), and
TGFα secretion was not detected in ELISA (data not
shown). In contrast to TGFα, EREG plays a key role in
EGFR activation in vitro. Highly elevated levels of OSM
were detected in PBMC supernatants only after priming,
while the protein was neither present in culture medium
nor in tumor cell-conditioned medium used to prime
PBMC (Figure 2C). Supernatants of primed PBMC
significantly upregulated pSTAT3 levels in the reporter
cell line, and STAT3 activation was reduced to basal
levels by OSM blockage (Figure 2B). Priming of PBMC,
enriched via adherence or purified via CD64/CD14 ex-
pression, resulted in similar levels of EGFR/STAT3
stimulation through EREG and OSM, confirming that
these two factors were indeed produced and secreted by
monocytic populations (Additional file 1: Figure S4A/B).
Accordingly, pro-EREG was present in PBMC, but not in
lymphocytes (Additional file 1: Figure S4C).
Together, these data indicate that that EREG, TGFA and
OSM transcription is induced in PBMC upon priming
with MDA-MB-231 supernatants. However, PBMC only
secrete functionally active EREG and OSM proteins.
Priming of differentiated macrophages significantly
increased HBEGF, AREG and OSM transcript levels
(Figure 2D). EREG levels, though upregulated in primed
MΦ, generally remain low in this cell type (Additional
file 1: Figure S1C). Upon priming, MΦ supernatants
significantly upregulated pEGFR levels in the reporter
Figure 1 Tumor cells and primary mononuclear cells interact via secreted factors. (A). Model for the interaction between tumor cells and
mononuclear cells. (B). Experimental approach for the study of effects of tumor cell supernatants (SN) on primary human PBMC and in vitro
differentiated MΦ.
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inhibitory antibody against HB-EGF. Though AREG tran-
scription was highly upregulated, a neutralising antibody
directed against AREG had no effect (Figure 2E). Superna-
tants of primed MΦ significantly elevated pSTAT3 levels
in the reporter cell line, and an antibody blocking OSM
function neutralised this effect (Figure 2E). Priming of
differentiated MΦ for seven days provoked secretion of
EGF family ligands and OSM to a similar extent (data
not shown). Quantitation of secreted HB-EGF and OSM
levels confirmed that secretion is significantly increased
by priming (Figure 2F). In contrast, AREG was not
secreted by primed MΦ (data not shown).
Taken together, these data indicate that, even though
various EGFR ligands are transcriptionally induced,
primed macrophages only secrete functionally active
HB-EGF and OSM.
Tumor-primed PBMC and MΦ display specific secretory
patterns
Tumor-primed PBMC and MΦ secrete one specific EGFR
agonist, respectively, in combination with OSM, the rele-
vant STAT3 activator. We next asked whether priming
with an expanded panel of tumor cell supernatants pro-
vokes similar response patterns in PBMC and MΦ. The
panel contained MDA-MB-231 (231), T-47D (T47), MCF7
(7), MDA-MB-468 (468) invasive mammary and SCC-9
(SCC) squamous carcinoma cell lines. MCF 10A (10A) are
derived from a benign breast lesion and primary HMEC
(HM) represent healthy breast epithelium.
After priming with 231, T47, 468 and 10A, PBMC
stereotypically co-secrete EGFR and STAT3 activators
(Additional file 1: Figure S5A). OSM was released in sig-
nificant quantities by tumor-primed PBMC (Additional
file 1: Figure S5B). Experiments with neutralising anti-
bodies confirmed that EREG and OSM were the only
functional EGFR and STAT3 activators secreted by
tumor-primed PBMC (Additional file 1: Figure S5C/D).
An overview of the factors secreted by PBMC upon
priming by various tumor cell lines is given in Table 1.
MΦ primed by 231, T47, 7 and SCC co-secreted consid-
erable amounts of HB-EGF and OSM (Table 1, Additional
file 1: Figure S6B), which were shown to be the only EGFR
and STAT3 activators released by primed MΦ (Additional
file 1: Figure S6C/D).
We observed clearly distinct priming capacities of tumor
cell lines on primary mononuclear cells: primary breast
epithelial cells (HM) derived from healthy donors neither
convey a secretory response in PBMC nor in MΦ (Table 1,
Additional file 1: Figure S5/S6). Selective PBMC priming
was achieved by 10A and 468 cells, while 7 and SCC cells
exclusively primed MΦ. 231 and T47 breast carcinoma
cells primed PBMC as well as MΦ (Table 1). Thus, a num-
ber of tumor cell lines triggers PBMC and MΦ to co-secrete an EGFR agonist and a STAT3 activator. The
secretory patterns of tumor-primed mononuclear cells are
lineage-specific: PBMC co-secrete EREG and OSM, while
MΦ co-secrete HB-EGF and OSM.HB-EGF and OSM are promigratory in epithelial cells
In the next set of experiments, we addressed functional
aspects of MΦ-derived HB-EGF and OSM on tumor cells.
HB-EGF promotes cell migration, invasion, proliferation
and survival [15,16]. Clinical and in vivo mouse data indi-
cate that HB-EGF drives tumor progression [17-19]. We
studied the effect of MΦ-secreted HB-EGF on tumor
cell migration in vitro. Supernatants of tumor-primed
MΦ increased SCC chemotaxis by 3.8-fold compared to
supernatants of control MΦ or priming medium alone.
An HB-EGF neutralising antibody or the EGFR inhibitor
AG1478 reduced migration to basal levels (Figure 3A).
Though originally reported as an antiproliferative fac-
tor [20], OSM failed to inhibit proliferation of several
breast cancer cell lines (Additional file 1: Figure S7A).
However, OSM induces the undirected motility of
MCF7 cells [21]. We incubated MCF7 cells for five days
at increasing doses of recombinant OSM. The Boyden
chamber assay confirmed a dose-dependent increase in
undirected MCF7 cell motility (Figure 3B). Similarly, a
2.6-fold increase in undirected motility was observed in
SCC-9 cells (Figure 3C).
10A, benign breast epithelial cells, are barely migratory
under most assay conditions. OSM did not induce motility
of 10A cells (data not shown). However, OSM-treated 10A
cells migrated two to three times faster along an HB-EGF
gradient (Figure 3D). For this cell line, HB-EGF is a potent
mitogen (Additional file 1: Figure S7B).
Taken together, prolonged treatment of MCF7 and SCC
cells with recombinant OSM induces undirected motility
in these tumor cells. Priming of MΦ by tumor cells results
in HB-EGF secretion at levels sufficient to drive cell
migration, and HB-EGF is the relevant chemotactic factor
for SCC cells secreted by primed MΦ. OSM and
HB-EGF cooperate in promoting chemotaxis of MCF
10A epithelial cells. All three cell lines express recep-
tors for OSM (Additional file 1: Figure S2) and EGFR
(Additional file 1: Figure S6A), [22,23].TAM express HB-EGF/OSM in invasive breast carcinoma
and HB-EGF plasma levels correlate with primary tumor
growth and lymph node involvement
According to the TAM/tumor cell interaction model, se-
creted factors produced by primed TAM might reach
the blood stream and be detected in blood samples of
cancer patients. Detection of elevated plasma levels of
TAM-secreted factors would specify the patient’s tumor
status. We determined HB-EGF and OSM plasma levels
Figure 2 (See legend on next page.)
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Figure 2 PBMC and MΦ display divergent patterns of transcript induction and ligand secretion upon priming by tumor cells. (A).
Primed PBMC induce EREG, TGFA and OSM transcripts. qPCR of control-treated (Ctrl) or MDA-MB-231-primed (Primed) PBMC. Means ± 95%
confidence intervals; *p < 0.05 by Mann-Whitney’s U-Test; n = 4. (B). Primed PBMC secrete EREG and OSM. PBMC supernatants were preincubated
with control sera or blocking antibodies, then used to stimulate reporter cells in which pEGFR, pSTAT3 and tubulin levels were visualised. Western
blots with densitometric analysis. Means ± SEM; n = 4; C: control Ig; T: TGFα blocking antibody; E: EREG blocking antibody; O: OSM blocking
antibody; *p < 0.02; **p < 0.006 by Student’s T-Test. (C). Primed PBMC secrete elevated OSM levels. ELISA of control-treated or MDA-MB-231-
primed PBMC. N: culture medium; P: priming medium; MC: control PBMC supernatant ; P-MC: primed PBMC supernatant; means ± SEM; n = 7;
*p < 0.002 by Mann-Whitney’s U-Test. (D). Primed MΦ upregulate AREG, EREG, HBEGF and OSM transcription. qPCR of control-treated or MDA-MB
-231-primed MΦ. Means ± 95% confidence intervals; *p < 0.02 by Mann-Whitney’s U-Test; n = 4. (E). Primed MΦ secrete HB-EGF and OSM. MΦ
were control-treated or MDA-MB-231-primed for 24 hrs. MΦ supernatants were preincubated with control sera or blocking antibodies, then used
to stimulate reporter cells in which pEGFR, pSTAT3 and tubulin levels were visualised. Western blots with densitometric analysis. Means ± SEM;
pEGFR: n = 6; pSTAT3: n = 12; H: HB-EGF blocking antibody; A: AREG blocking antibody; O: OSM blocking antibody. **p < 0.00006 by Student’s
T-Test. (F). Primed MΦ secrete elevated HB-EGF and OSM levels. ELISA of control-treated or MDA-MB-231-primed MΦ. N: culture medium;
P: priming medium; MΦ: control macrophage supernatant; P-MΦ: primed macrophage supernatant; means ± SEM; n = 6; *p < 0.004 by
Mann-Whitney’s U-Test.
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102 female patients with ductal carcinoma in situ (DCIS)
or invasive breast carcinoma were analysed. 26 healthy
female donors served as controls. A highly significant
correlation is apparent between plasma HB-EGF and
OSM protein levels (Figure 4A and Additional file 1:
Table S1; Pearson correlation value: 0.722; 95% confidence
interval: 0.628 to 0.795; p = 2.2e-16). In healthy donors,
HB-EGF and OSM concentrations were constitutively low
(mean HB-EGF concentration: 21.2 pg/ml; mean OSM
concentration: 13.8 pg/ml). Interestingly, the concerted se-
cretion of both ligands was also detected in two fibroaden-
oma patients and one patient with Crohn’s disease
(Additional file 1: Figure S8).
Given that HB-EGF levels were elevated in a larger
proportion of patients’ plasma samples, we reasoned that
HB-EGF plasma levels might correlate with growth and/
or progression of mammary carcinomas. Mean plasma
concentrations of HB-EGF reflect primary tumor size:
for small tumors (pT1; 23 patients) we detected 29.6 pg/
ml, medium sized tumors (pT2; 13 patients) displayed
62.1 pg/ml and large tumors (pT3; 9 patients) 131.8 pg/
ml. In conclusion, HB-EGF plasma levels correlated with
primary tumor size (Figure 4B).
In addition, elevated HB-EGF plasma levels also correl-
ate with lymph node dissemination of mammary breast
carcinomas (Figure 4C): healthy donors (Ctrl; n = 26)
and lymph node negative invasive mammary carcinoma
patients (pN0; n = 26) displayed mean HB-EGF plasma
concentrations of 21.2 pg/ml and 24.6 pg/ml, respectively,
whereas significantly elevated HB-EGF levels were
detected in patients with disseminated tumors (97.5 pg/
ml; pN > 0; n = 28).
We defined the mean plasma HB-EGF concentration
of healthy donors (21.2 pg/ml; Figure 4A) as a threshold
that grouped invasive breast carcinoma patients into an
HB-EGF negative or HB-EGF positive cohort. In this
scoring, 50% (27 of 54) of the patients were determined
HB-EGF positive, and tumor cell positive lymph nodeswere detected in 52% (28 of 54) of the patients. How-
ever, 70% (19 of 27) of HB-EGF positive patients were
diagnosed with disseminated tumors, whereas only 33%
(9 of 27) of the HB-EGF negative cohort were lymph node
positive (Figure 4D). In conclusion, mammary carcinoma
patients with disseminated tumors can be identified by
elevated HB-EGF plasma levels.
To test a potential participation of monocyte-secreted
EREG in the development of mammary tumors, we quan-
tified EREG plasma protein levels in 59 donors with DCIS
or invasive mammary carcinomas as well as in 10
healthy donors. In the control donors and in the major-
ity of breast cancer patients, EREG plasma levels
remained low (Additional file 1: Figure S9). We only
detected elevated EREG levels in 5 of 59 cancer patients,
rendering a significant contribution of monocyte-derived
EREG to the progression of breast cancer implausible. A
supplementary list containing ELISA and clinical patient
data is available online (Additional file 2).
To test whether TAM express HB-EGF and OSM
in vivo, we performed immunohistochemical analysis of
paraffin-embedded tissue samples of breast cancer pa-
tients with elevated HB-EGF plasma levels. Our analysis
confirmed that TAM co-expressed HB-EGF and OSM
in primary tumors (Figure 5A). Compared to HB-EGF
negative patients, we observed an increase in TAM density
in tumors of HB-EGF positive patients (Figure 5B). Quan-
titation of TAM numbers in patients with elevated HB-
EGF plasma levels (n = 12) and HB-EGF negative patients
(n = 9) revealed a highly significant correlation between
HB-EGF plasma levels and TAM infiltration (Figure 5C).
Corroborating our previous observation that increased
plasma levels of HB-EGF are primarily found in patients
with large primary tumors, increased TAM densities also
significantly correlate with tumor size (Figure 5D).
Confirming our in vitro interaction model, the presented
immunohistochemical data identify TAM as sources of
production of HB-EGF and OSM in primary tumors. Ele-
vated HB-EGF and OSM levels in patients’ plasma
Table 1 Tumor-secreted factors induce specific secretory
patterns in PBMC and MΦ
Priming
supernatant
PBMC MΦ
EREG OSM HB-EGF OSM
MDA-MB-231 + + + +
T-47D + + + +
MCF7 - - + +
MDA-MB-468 + + - -
SCC-9 - - + +
HMEC - - - -
MCF 10A + + - -
PBMC and MΦ were primed with the indicated supernatants and secretion of
EREG, HB-EGF and OSM was assessed. Detailed data are presented in
Additional file 1: Figures S5, S6.
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carcinomas in vivo.
Given the strong correlation between TAM density, HB-
EGF plasma levels and tumor size, increased HB-EGF
plasma levels identify a substantial part of node positive
patients, connecting TAM-secreted HB-EGF with tumor
dissemination.Tumor HBEGF expression is predominantly localised in
the stromal compartment
To further substantiate the clinical data, we analysed tumor
microarray datasets available at Oncomine™. The breast
carcinoma microarray dataset by Ambs and colleagues dis-
tinguished between genes expressed by tumor cells ver-
sus stromal cells [24]. Our analysis of this dataset
revealed that both HBEGF and the monocytic marker
CD64 are predominantly expressed in the stromal com-
partment (Additional file 1: Figure S10A), suggesting
that tumor-associated mononuclear cells express this
EGFR agonist.
In our experiments, priming of differentiated MΦ was
not restricted to mammary carcinoma cell lines. MΦ-
derived factors are also functional in other carcinomas.
Analysis of the bladder carcinoma microarray dataset
published by Radvanyi and colleagues [25] showed
HBEGF to be overrepresented in infiltrating carcinoma
samples (Additional file 1: Figure S10B). These data cor-
roborate our in vitro findings that HB-EGF is involved
in the progression of a variety of carcinomas.Discussion
Recent scientific advances have established that mono-
cytes and macrophages are not only critically involved in
inflammatory processes such as pathogen defence and
wound healing, but also play an active role in cancer de-
velopment. Their functions are modulated by tumor cells,
resulting in tolerant, trophic phenotypes indispensable for
tumor progression [6]. Among the factors secreted bytumor cells the chemokine CCL2 has been identified as an
important priming factor of TAM in vivo [26]. Based on a
model that tumor cells and mononuclear cells communi-
cate via secreted factors, we have used cell supernatants to
study the reciprocal influence of both cell types. Our main
focus was on the paracrine release of both EGFR and
STAT3 activators by monocytes/macrophages to tumor
cells [6]. The presented data indicate that the differen-
tiation process of monocytes to macrophages is of no
importance for the activation of these two signaling
pathways, even though the precise nature of the se-
creted ligands changes with differentiation.
Constitutive activation of STAT3 is common in melan-
oma, breast, head and neck, lung, pancreatic and pros-
tate cancer [27]. Tumor-primed primary PBMC and MΦ
secrete oncostatin-M, and only OSM activates STAT3 in
our reporter system. Both OSM receptors are exclusively
found in epithelial and carcinoma cells. This underscores
the unique paracrine role of mononuclear cell-derived
OSM acting on tumor cells. This is the first report that
shows tumor cell-derived activities to induce OSM se-
cretion by primary human PBMC and MΦ, supporting
an interaction model defined by mutually secreted fac-
tors. All of the tested tumor cell lines effectively primed
human PBMC and/or differentiated MΦ. Priming in-
duced rather complex transcriptional induction profiles
of EGFR ligands in mononuclear cells. At protein level,
however, priming resulted in co-secretion of EREG and
OSM by PBMC, while tumor-primed MΦ co-secreted
HB-EGF and OSM in vitro. Transcript analysis alone,
however, would not reliably predict the functionally rele-
vant EGFR agonist released by tumor-primed mononuclear
cells [28]. In summary, two secretory patterns emerge in
PBMC and MΦ in response to tumor cell-secreted factors:
a lineage-specific EGFR ligand in combination with OSM.
Functionally, recombinant OSM and HB-EGF strongly
cooperate in inducing chemotaxis of benign breast cells
in vitro. OSM enhances the intrinsic motility of carcinoma
cells, while macrophage-produced HB-EGF is the key
chemotactic factor for squamous cell carcinoma cells in
our assays. Our in vitro data suggest that TAM-derived
OSM and HB-EGF influence migratory processes of can-
cer cells. In breast cancer patients, HB-EGF and OSM are
co-expressed by TAM and plasma protein levels of both li-
gands correlate strongly. Elevated HB-EGF plasma protein
levels are strongly associated with primary tumor growth
and lymph node dissemination in invasive breast cancer
patients. In fact, the majority of lymph node positive pa-
tients display elevated HB-EGF plasma levels. Increased
density of infiltrating TAM in patients with elevated
HB-EGF plasma levels further supports the hypothesis
that TAM-secreted HB-EGF promotes breast carcinoma
growth and metastasis in vivo. HBEGF transcripts prima-
rily detected in the stroma of mammary carcinomas
Figure 3 (See legend on next page.)
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Figure 4 Systemic protein levels of HB-EGF and OSM are elevated in breast carcinoma patients. (A). HB-EGF and OSM plasma protein
levels correlate in human donors. Plasma from 26 control donors and 102 breast carcinoma patients was analysed. Pearson’s correlation
coefficient between HB-EGF and OSM levels: 0.722; 95% confidence interval: 0.628 to 0.795; p < 2.2e-16 (alternative hypothesis: true correlation is
not equal to 0). (B). HB-EGF plasma protein levels correlate with primary tumor size in patients with invasive breast carcinoma. Box plots show
HB-EGF plasma levels of 26 control donors, 23 pT1 donors, 13 pT2 donors and 9 pT3 donors. P-values by Mann-Whitney’s U-Test are: Ctrl-pT2:
0.0058; Ctrl-pT3: 0.0003; pT1-pT2: 0.0017; pT1-pT3: 0.0008. (C). HB-EGF plasma protein levels correlate with lymph node dissemination of invasive
breast carcinoma. Box plots depict HB-EGF levels of control donors (Ctrl; n = 26), donors with nodal negative (pN0; n = 26) and with nodal
positive disease (pN > 0; n = 28). (D). Elevated HB-EGF plasma levels are indicative of disseminating breast carcinomas. Invasive breast carcinoma
patients (n = 54) were grouped into an HB-EGF negative (-; n = 27) and HB-EGF positive (+; n = 27) cohort, using the mean plasma HB-EGF
concentration of control donors (21.2 pg/ml; n = 26) as a threshold. 70% (19/27) of HB-EGF positive patients had disseminated tumors, whereas
only 33% (9/27) of HB-EGF negative patients were lymph node positive. p = 0.020 by Mann Whitney’s U-Test. Conditional probabilities: P(pN > 0 |
HB-EGF+) = 0.704 and P(pN > 0 | HB-EGF-) = 0.333.
(See figure on previous page.)
Figure 3 HB-EGF and OSM promote epithelial cell migration. (A). HB-EGF secreted by primed MΦ induces chemotaxis of SCC-9 cells. MΦ
were cultured for 6 days in either control medium or 50% MDA-MB-231-conditioned medium. Subsequently, cells received 50% MDA-MB-231-
conditioned serum-free medium or RPMI for 24 hrs. MΦ supernatants were collected and used as chemoattractants for SCC-9 cells in Boyden
chamber assays. Where indicated, media were preincubated with control Ig (C), an HB-EGF blocking antibody (H) or 250 nM EGFR kinase inhibitor
AG1478 (AG). Representative experiment with corresponding micrographs. N: culture medium; P: priming medium; MΦ: supernatant of control
macrophages; P-MΦ: supernatant of primed macrophages; scale bar: 200 μm; n = 3; *p < 0.05 by Student’s T-Test. (B). OSM promotes motility of
MCF7 cells. Cells were incubated for 5 days with or without the indicated concentrations of recombinant OSM. Subsequently, cells were plated
into Boyden chambers, using the same dose of OSM in RPMI + 2% FCS in the upper and lower compartments. (C). OSM promotes motility of
SCC-9 cells. Cells were incubated for 48 hrs with or without 10 ng/ml recombinant OSM, and were subsequently plated into Boyden chambers,
using the same dose of OSM in RPMI in the upper and lower compartments. Results are means ± SEM; n = 4; *p < 0.05 by Student’s T-Test. (D).
HB-EGF and OSM cooperate in promoting chemotaxis of MCF 10A cells. Cells were cultured for 48 hrs with or without the indicated
concentrations of recombinant OSM. Subsequently, cells were plated into Boyden chambers, using the same concentration of OSM in RPMI in
the upper and lower compartments. Where indicated, 2 ng/ml recombinant HB-EGF was used as a chemoattractant in the lower compartment.
Results are means ± SEM; n = 3; *p < 0.05 by Student’s T-Test; micrographs show a representative experiment; scale bar: 200 μm.
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Figure 5 HB-EGF and OSM are co-expressed by TAM in breast carcinomas. (A) TAM co-express HB-EGF and OSM. Paraffin-embedded tumor
specimens of breast carcinoma patients with elevated HB-EGF plasma levels were stained with an antibody detecting the macrophage marker
CD68. Consecutive slides were stained with antibodies against HB-EGF and OSM. Representative micrographs. Scale bar: 50 μm. (B). Primary
tumors of HB-EGF positive breast carcinoma patients are densely infiltrated by TAM. Macrophages were detected by a monoclonal anti-CD68
antibody as in (A). Representative micrographs show macrophage infiltrates in tumor samples of HB-EGF positive and negative patients. Healthy
breast stromal tissue is largely devoid of macrophage infiltrates. Scale bar: 50 μm. (C). Elevated HB-EGF plasma levels correspond to increased
TAM density in breast carcinoma patients. TAM in paraffin-embedded primary tumor samples of patients with elevated HB-EGF plasma levels (+;
n = 12; mean HB-EGF concentration: 222.1 pg/ml) and of HB-EGF negative patients (-; n = 9) were identified by anti-CD68 staining. TAM numbers
were quantified in 6 high power fields per patient (HPF). Scatter plots indicate mean values for each patient (dots) and mean values for both
cohorts (horizontal bars). p = 0.0036 by Mann-Whitney’s U-Test. (D). TAM density correlates with tumor size in breast carcinoma patients. Tumor-
infiltrating macrophages were quantified as in (C). Patients were divided into two cohorts according to tumor size (pT1: tumor size ≤ 2 cm;
n = 12; pT > 1: tumor size > 2 cm; n = 9). p = 0.0012 by Mann-Whitney’s U-Test.
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supporting the assumption that TAM account for the ex-
pression of HBEGF in the tumor microenvironment. Our
analysis of the Stransky bladder carcinoma microarray
data [25] corroborated these findings inasmuch as HBEGF
transcript levels increase in infiltrating tumors with re-
spect to superficially growing lesions. In bladder carcin-
omas, HBEGF transcript levels inversely correlate with
patients’ survival times [19]. As Massagué and co-workers
have shown in a mouse xenograft model, HBEGF sustains
the specific dissemination of human mammary tumor
cells to the brain, whereas dissemination to the lung is
accompanied by EREG expression [29,30]. Elevated
EREG plasma protein levels, however, were detected in
a minor fraction of our breast cancer patient data set,
suggesting that EREG is not a primary contributor to
breast cancer progression mediated by monocytes in
humans. Immunohistochemical studies of HB-EGF ex-
pression in breast carcinoma tumor cells have found no[31] or an inverse correlation [32] to tumor progression
parameters, whereas our study indicates a positive con-
tribution of TAM-derived HB-EGF production in the
primary tumor to invasive mammary carcinoma pro-
gression. TAM expression of HB-EGF has been reported
for cholangiocarcinoma metastases. Additionally, this
report linked the priming of mononuclear cells to HB-
EGF expression in vitro [33].
Inflammatory processes have been studied in wound
healing, and macrophages play a key role in skin repair
[34]. In this process, only infiltrating polymorphonuclear
neutrophils have yet been described to secrete OSM [35],
and HB-EGF is detected in wound exudates [36].
Our work focuses on paracrine factors secreted by
mononuclear cells upon priming by tumor cells. This
priming process induces secretory patterns that consist-
ently feed back to activate oncogenic EGFR- and STAT3
pathways in tumor cells. We identify HB-EGF and OSM
as the key EGFR and STAT3 activators secreted by
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activating factors secreted by tumor-primed PBMC.
HB-EGF and OSM profoundly influence tumor cell
behaviour and cooperatively promote cell motility. Our
in vitro results indicate that these proteins effectively
mediate macrophage-assisted cancer progression. The
identified stereotype secretion patterns are elementary
to design strategies to interfere with pro-tumorigenic
mononuclear functions by inhibiting HB-EGF, EREG
and OSM. In particular, HB-EGF function is apparently
connected to tumor growth and dissemination. But first,
a clear clinical characterisation of the subset of tumors infil-
trated by pro-tumorigenic mononuclear cells is essential. In
particular, HB-EGF serves as potential blood-bound marker
allowing the minimally invasive identification of tumors
supported by TAM. Our work describes pro-tumorigenic
marker proteins that identify tumor-supportive mono-
nuclear cells and establishes a basis for therapeutic inter-
vention aimed at neutralising these STAT3 and EGFR
activators at the molecular level.
Conclusions
Soluble tumor-cell-derived factors trigger mononuclear
cells to co-secrete lineage-specific EGFR agonists together
with a common STAT3 activator. Tumor-primed MΦ re-
lease HB-EGF and OSM, while tumor-primed PBMC co-
secrete EREG and OSM. TAM co-express HB-EGF and
OSM in primary mammary carcinoma samples. In these
patients, HB-EGF plasma protein levels strongly correlate
with TAM infiltration levels, primary tumor size and
lymph node dissemination, indicating that TAM-derived
HB-EGF supports carcinoma progression. Thus, HB-EGF
plasma protein levels are a potential marker indicating a
pro-tumor reaction of TAM in mammary carcinoma.
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